ARVN
Arvinas Inc
Halal Rating :
Last Price
$18.04
Last updated:
Market Cap
-
7D Change
0.17%
1 Year Change
-50.64%
Company Overview
Industries
Exchange
Next Earnings Date
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. The company's proprietary PROTAC® (PROteolysis TArgeting Chimera) technology platform is designed to degrade disease-causing proteins. Their lead product candidates include bavdegalutamide (ARV-110) for metastatic prostate cancer and ARV-471 for patients with breast cancer.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $102.4m | $162.7m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $76.5m | $125.0m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $25.3m | $108.6m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Arvinas Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.